# An Open Trial to Assess the Tolerability of AVANZ® Salsola Immunotherapy

> **NCT02065856** · PHASE2 · COMPLETED · sponsor: **ALK-Abelló A/S** · enrollment: 51 (actual)

## Conditions studied

- Allergic Rhinoconjunctivitis Due to Salsola Kali Pollen

## Interventions

- **BIOLOGICAL:** AVANZ Salsola

## Key facts

- **NCT ID:** NCT02065856
- **Lead sponsor:** ALK-Abelló A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2014-08
- **Final completion:** 2014-12
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2015-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02065856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02065856, "An Open Trial to Assess the Tolerability of AVANZ® Salsola Immunotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02065856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*